Skip to main content
. Author manuscript; available in PMC: 2017 Feb 8.
Published in final edited form as: Nat Med. 2016 Aug 8;22(9):1056–1061. doi: 10.1038/nm.4155

Figure 2. Knockdown of STAG2 or STAG3 decreases BRAFi sensitivity in BRAF mutant melanoma cells.

Figure 2

(a) Viability of A375 cells after treatment with varying concentrations of dabrafenib for 3 d. Experiment was performed 3 times. Data are mean ± s.e.m. (b) A375 cells were treated with dabrafenib for 2 h. Cell lysates were used for western blotting with indicated antibodies. Experiment was performed 3 times. (c) Viability of SKMEL28 cells after treatment with varying concentrations of vemurafenib for 3 d. Experiment was performed 3 times. Data are mean ± s.e.m. (d) SKMEL28 cells were treated with vemurafenib for 2 h. Cell lysates were used for western blotting with indicated antibodies. Experiment was performed 3 times. (e) SKMEL30 cells were treated with trametinib for 2 h. Cell lysates were used for western blotting with indicated antibodies. Experiment was performed 3 times. (f) SKMEL30 cells were treated with trametinib as indicated in clonogenic growth assays. Experiment was performed 3 times. Scale bar: 5 mm. (g) Viability of A375 cells after treatment with varying concentrations of dabrafenib for 3 d. Experiment was performed 3 times. Data are mean ± s.e.m. (h) A375 cells were treated with vemurafenib for 2 h. Cell lysates were used for western blotting with indicated antibodies. Experiment was performed 3 times. (i) WM902-BR cells stably expressing control vector, FLAG-tagged wild-type STAG2 (WT), Lys1083* (K*) or Asp193Asn (DN) mutants were treated with 3 μM vemurafenib for 2 h. Cell lysates were used for western blotting with indicated antibodies. Experiment was performed 3 times. (j) WM902-BR cells were used in soft agar assays in the presence or absence of 3 μM vemurafenib. Experiment was performed 3 times. Scale bar: 5 mm.